One trial that includes patients with RHO‐associated disease (NCT05203939) entails delivery, not of the RHO gene, but of nuclear hormone receptor‐based gene modification therapy, inspired by mouse models in which Nr2e3 gene therapy ameliorated degeneration in diverse genetic causes of RP [143]. Here, RHO is linked to retinitis pigmentosa 1.